Search

Your search keyword '"Walker, Zuzana"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Walker, Zuzana" Remove constraint Author: "Walker, Zuzana" Journal alzheimer's & dementia Remove constraint Journal: alzheimer's & dementia
47 results on '"Walker, Zuzana"'

Search Results

1. Sex differences in brain atrophy in dementia with Lewy bodies

3. Dysfunctional cerebral glucose transport in Alzheimer’s Disease

5. The association between Aβ aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort

6. A Centiloid cut‐off to help predict true amyloid accumulation

7. MRI CHANGES FOLLOWING TREATMENT OF GLP‐1 ANALOGUE, LIRAGLUTIDE IN ALZHEIMER’S DISEASE

8. AMYPAD: Correlation of Amyloid PET results with anxiety and depressive symptoms in SCD+, MCI and dementia patients

9. APPLE‐Tree remote secondary dementia prevention; opportunities for scalable public health interventions to reduce dementia risk

11. Magnetic Resonance Spectroscopy metabolites as biomarkers of Alzheimer’s Disease

12. Progress on the Development of the Lewy Body Dementia‐Domain Rating Scale

13. Steps towards the implementation of amyloid‐PET in memory clinics: AMYPAD Diagnostic and Patient Management Study

14. The Deep Dementia Phenotyping (DEMON) Network: A global platform for innovation using data science and artificial intelligence

15. The Deep Dementia Phenotyping (DEMON) Network: A global platform for innovation using data science and artificial intelligence

17. Self‐reflection is associated with markers of Alzheimer’s disease in cognitively unimpaired older adults

18. Effectiveness of lifestyle and psychosocial interventions in reducing cognitive decline in older people: Systematic review

19. Impact of the disclosure of amyloid‐PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS)

20. Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects

21. Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease

22. Stakeholders’ views around the concept and diagnosis of mild cognitive impairment and their understanding of dementia prevention: A qualitative study

23. Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease

24. Behavioural symptoms in Alzheimer’s disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism

25. P2-358: INSULIN RESISTANCE INFLUENCES HIPPOCAMPAL GLUCOSE METABOLISM RATHER THAN HIPPOCAMPAL VOLUME IN NON-DIABETIC ALZHEIMER'S DISEASE PATIENTS

26. P3-328: DOES INSULIN RESISTANCE INFLUENCE WHITE MATTER LESIONS IN NON-DIABETIC AD SUBJECTS?

27. P3-373: AMYPAD-DPMS PRELIMINARY RESULTS: PARTICIPANTS’ BASELINE FEATURES

28. AMYPAD Diagnostic and Patient Management Study: Rationale and design

29. P3‐225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON‐DIABETIC ALZHEIMER'S PATIENTS

32. THE AMYPAD-DX CONTROLLED TRIAL ON THE DIAGNOSTIC VALUE OF AMYLOID PET

35. O4-06-03: PREVALENCE OF DLB FEATURES IN POSSIBLE DEMENTIA WITH LEWY BODIES AND ITS RELATIONSHIP TO CHANGES IN DEMENTIA DIAGNOSTIC CATEGORY AFTER DOPAMINE TRANSPORTER IMAGING USING DATSCAN™

36. P4-345: THE LONG-TERM CLINICAL EFFECTIVENESS OF START (STRATEGIES FOR RELATIVES) FOR FAMILY CARERS OF PEOPLE WITH DEMENTIA AND THE EFFECTS ON COST OF CARE

37. P2–097: Changes in dementia diagnostic category and diagnostic confidence following dopamine transporter SPECT imaging (DaTscanTM ‐ Ioflupane 123I) in people with an uncertain diagnosis of dementia with Lewy bodies (possible DLB)

43. O4‐07‐02: Efficacy and safety of florbetaben for beta‐amyloid brain positron emission tomography in Alzheimer's disease: Results from a global phase IIb trial

Catalog

Books, media, physical & digital resources